116 related articles for article (PubMed ID: 14586481)
1. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m(2)).
Palumbo A; Bringhen S; Bertola A; Cavallo F; Falco P; Massaia M; Bruno B; Rus C; Barbui A; Caravita T; Musto P; Pescosta N; Rossini F; Vignetti M; Boccadoro M
Leukemia; 2004 Jan; 18(1):133-8. PubMed ID: 14586481
[TBL] [Abstract][Full Text] [Related]
2. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
Palumbo A; Bringhen S; Bruno B; Falcone AP; Liberati AM; Grasso M; Ria R; Pisani F; Cangialosi C; Caravita T; Levi A; Meloni G; Nozza A; Pregno P; Gabbas A; Callea V; Rizzo M; Annino L; De Stefano V; Musto P; Baldi I; Cavallo F; Petrucci MT; Massaia M; Boccadoro M
Blood; 2010 Mar; 115(10):1873-9. PubMed ID: 19965659
[TBL] [Abstract][Full Text] [Related]
3. Triple MEL100 therapy in multiple myeloma.
Berz D; Colvin GA; McCormack EM; Winer ES; Karwan P; Colvin L; Rathore R; Lum LG; Elfenbein GJ; Quesenberry PJ
Transplant Proc; 2009 Nov; 41(9):3863-7. PubMed ID: 19917402
[TBL] [Abstract][Full Text] [Related]
4. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients.
Palumbo A; Triolo S; Argentino C; Bringhen S; Dominietto A; Rus C; Omedè P; Tarella C; Pileri A; Boccadoro M
Blood; 1999 Aug; 94(4):1248-53. PubMed ID: 10438712
[TBL] [Abstract][Full Text] [Related]
5. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial.
Palumbo A; Bringhen S; Petrucci MT; Musto P; Rossini F; Nunzi M; Lauta VM; Bergonzi C; Barbui A; Caravita T; Capaldi A; Pregno P; Guglielmelli T; Grasso M; Callea V; Bertola A; Cavallo F; Falco P; Rus C; Massaia M; Mandelli F; Carella AM; Pogliani E; Liberati AM; Dammacco F; Ciccone G; Boccadoro M
Blood; 2004 Nov; 104(10):3052-7. PubMed ID: 15265788
[TBL] [Abstract][Full Text] [Related]
6. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
7. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
Child JA; Morgan GJ; Davies FE; Owen RG; Bell SE; Hawkins K; Brown J; Drayson MT; Selby PJ;
N Engl J Med; 2003 May; 348(19):1875-83. PubMed ID: 12736280
[TBL] [Abstract][Full Text] [Related]
8. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
9. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD
Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952
[TBL] [Abstract][Full Text] [Related]
10. Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients.
Palumbo A; Triolo S; Baldini L; Callea V; Capaldi A; De Stefano V; Grasso M; Liberati M; Lotesoriere C; Marcenò R; Marmont F; Musto P; Petrucci MT; Spriano M; Pileri A; Boccadoro M
Haematologica; 2000 May; 85(5):508-13. PubMed ID: 10800168
[TBL] [Abstract][Full Text] [Related]
11. Full or intensity-reduced high-dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma.
Straka C; Salwender H; Knop S; Vogel M; Müller J; Metzner B; Langer C; Sayer H; Jung W; Dürk HA; Bassermann F; Gramatzki M; Rösler W; Wolf HH; Brugger W; Engelhardt M; Fischer T; Liebisch P; Einsele H
Eur J Haematol; 2021 Nov; 107(5):529-542. PubMed ID: 34270825
[TBL] [Abstract][Full Text] [Related]
12. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
13. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone.
Desikan KR; Tricot G; Dhodapkar M; Fassas A; Siegel D; Vesole DH; Jagannath S; Singhal S; Mehta J; Spoon D; Anaissie E; Barlogie B; Munshi N
Bone Marrow Transplant; 2000 Mar; 25(5):483-7. PubMed ID: 10713623
[TBL] [Abstract][Full Text] [Related]
14. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
Facon T; Mary JY; Hulin C; Benboubker L; Attal M; Pegourie B; Renaud M; Harousseau JL; Guillerm G; Chaleteix C; Dib M; Voillat L; Maisonneuve H; Troncy J; Dorvaux V; Monconduit M; Martin C; Casassus P; Jaubert J; Jardel H; Doyen C; Kolb B; Anglaret B; Grosbois B; Yakoub-Agha I; Mathiot C; Avet-Loiseau H;
Lancet; 2007 Oct; 370(9594):1209-18. PubMed ID: 17920916
[TBL] [Abstract][Full Text] [Related]
15. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
16. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
18. Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients.
Palumbo A; Pileri A; Triolo S; Omedè P; Bruno B; Ciravegna G; Galliano M; Frieri R; Boccadoro M
Bone Marrow Transplant; 1997 Jan; 19(1):23-9. PubMed ID: 9012927
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P;
J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
